FIELD: chemistry.
SUBSTANCE: invention also relates to a non-solvated crystalline form of the hydrochloride salt of 5-[3-(3-hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2-diphenylhexanamide, a pharmaceutical composition, use of compounds in claim 1 or 2, as well as a method of treating a mammal with M3 antagonist.
EFFECT: obtaining novel biologically active compounds which have M3 antagonist activity.
9 cl, 6 ex, 1 tbl
Authors
Dates
2011-06-27—Published
2008-03-06—Filed